Drugs often exert their effects by binding to targets within cells to alter subsequent actions of the target in an effort to treat disease. Below is the Therapeutic Target Dashboard summarizing evidence for treatments of HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) that have been published in scientific literature. We were inspired by our colleagues at the Chordoma Foundation (https://www.chordomafoundation.org/targets/). While only two clinical trials have been performed on drugs specifically to treat idiopathic multicentric Castleman disease (iMCD), the evidence compiled below suggests that additional targets including different proteins and signaling pathways can serve as therapeutic targets for treatment of iMCD.
|Treatment Target||Treatment||Molecular Evidence (Rationale)||Case Reports (Potential/Tested Therapies)||Clinical Trials for iMCD|
|IL-6||Siltuximab||yes||yes||yes, approved by FDA in 2014|
|Tocilizumab||yes||yes||yes, approved by Japanese regulatory agency in 2005|
|Nonspecific cytotoxic immuno-depletion||CHOP||yes||yes|
|Non-specific immune activation||Corticosteroids||yes||yes|
This therapeutic target database was last updated 4/2017.